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Bloodstream infection (BSI) is the most common infectious complication of hematopoietic stem cell trans-
plantation (HSCT) and can cause substantial morbidity and mortality. Identiﬁcation of risk factors for BSI
might be helpful in efforts to reduce transplantation-related death. This study analyzed the incidence of BSI
and risk factors for BSI after HSCT in pediatric patients with aplastic anemia (AA). BSI occurred in 39 of the
351 patients with AA (11.1%). Onset of BSI occurred at a median of 8 days after HSCT (range, 0 to 92 days). The
5-year overall survival rate was lower in patients with BSI than in patients without BSI (63.32%  7.90% versus
93.35%  1.44%; P < .0001). Univariate analysis identiﬁed the following variables as associated with BSI:
history of immunosuppressive therapy with antithymocyte globulin (ATG), transplantation from an unrelated
donor, frequent blood transfusion before transplantation, major or major plus minor ABO type mismatch,
graft-versus-host disease prophylaxis with tacrolimus and without cyclosporine, and long interval from
diagnosis to transplantation. Among these factors, long interval from diagnosis to transplantation was the
sole statistically signiﬁcant risk factor for BSI on multivariate analysis. In patients who underwent HSCT from
a related donor, age 14 years at transplantation was risk factor for BSI. In contrast, history of immuno-
suppressive therapy with ATG, frequent blood transfusion before HSCT, graft failure, and major or major plus
minor ABO type mismatch were risk factors for BSI in patients who underwent HSCT from an unrelated donor.
Because the overall 5-year survival rate without BSI was >90%, even in patients who were received a
transplant from an unrelated donor, control of BSI is very important for successful HSCT in pediatric patients
with AA.
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Hematopoietic stem cell transplantation (HSCT) is ﬁrst-
line therapy for severe aplastic anemia (AA). HSCT from an
HLA-matched sibling donor is an established standarddgments on page 1149.
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high survival rates [1]. Outcomes of HSCT from an unrelated
donor have gradually improved [2,3].
Bloodstream infection (BSI) is the most common infec-
tious complication of HSCT and causes substantial morbidity
and mortality [4,5]. Identiﬁcation of risk factors for BSI may
aid efforts to reduce transplantation-related deaths. We
previously identiﬁed AA as a common risk factor for BSI in a
retrospective multicenter study [6]. In the present study, we
analyzed the incidence of BSI and risk factors for BSI afterTransplantation.
Table 1
Organisms Isolated from Blood Cultures of Patients with AA Who Un-
derwent HSCT
R. Kobayashi et al. / Biol Blood Marrow Transplant 20 (2014) 1145e11491146HSCT in pediatric patients with AA using the Transplant
Registry Uniﬁed Management Program (TRUMP) system of
the Japanese Society of Stem Cell Transplantation.Organism n
Staphylococcus 11
Staphylococcus epidermidis 8
Staphylococcus haemoliticus 1
Coagulase-negative staphylococci 1
Staphylococcus sp 1
Streptococcus 7
Streptococcus mitis 4
Streptococcus viridans 1
a-streptococci 1
Streptococcus sp 1
Micrococcus 1
Enterococcus 1
Bacillus 4
Gram-positive rods 1
Escherichia coli 1
Enterobacter cloacae 2
Acinetobacter 1
Pseudomonas aeruginosa 4
Stenotrophomonas maltophilia 3
Candida 3PATIENTS AND METHODS
Between 1980 and 2011, 1098 patients age 19 years who underwent
HSCT for AA (excluding hereditary bone marrow failure, paroxysmal
nocturnal hemoglobinemia, and secondary AA) were registered with the
TRUMP system of the Japanese Society of Stem Cell Transplantation. Of these
1098 patients, 516 who underwent HSCT before 2000 were excluded from
this analysis, owing to the drastic changes in infection control practices
promulgated by the Japanese Society of Stem Cell Transplantation in 2000,
including antibiotics and antifungal drugs and guidelines for infection
management in the early post-transplantation period. Of the remaining 582
patients, 231 were excluded due to insufﬁcient data; thus, our study group
comprised 351 pediatric patients with AA who underwent HSCT, including
193 males and 158 females, with a median age of 11 years (range, 0 to 19
years).
Diagnosis and assessment of severity of disease were established ac-
cording to published criteria [7]. Severity of AA at initial diagnosis was as
follows: very severe, n¼ 84; severe, n¼ 137; nonsevere, n¼ 130. Severity of
AA at HSCT was as follows: very severe, n¼ 122; severe, n¼ 166; nonsevere,
n ¼ 63. The median interval from diagnosis to transplantation was 337 days
(range, 9 to 5261 days). Two hundred and seventy-eight patients had
received some speciﬁc treatment for AA before transplantation, including
steroids (n ¼ 171), antithymocyte globulin (ATG; n ¼ 210), cyclosporine
(CsA; n ¼ 244), and granulocyte colony-stimulating factor (n ¼ 141). Stem
cell source was bone marrow in 315 patients, peripheral blood in 12 pa-
tients, bone marrow plus peripheral blood in 1 patient, and cord blood in 23
patients. One hundred seventy-three patients had a related donor, 1 patient
had a syngeneic donor, and 177 patients had an unrelated donor.
The conditioning regimen included ATG for 240 patients, cyclophos-
phamide for 317, ﬂudarabine for 244, melphalan for 39, total body irradia-
tion for 145, thoracoabdominal irradiation for 49, and total lymphoid
irradiation for 70 patients. Graft-versus-host disease (GVHD) prophylaxis,
deﬁned as planed administration of immunosuppressive drugs before evi-
dence of acute GVHD, included steroids in 17 patients, CsA in 160, tacrolimus
in 191, and methotrexate in 319.
Twenty-four patients underwent a second HSCT, 3 patients underwent a
third HSCT, and 1 patient underwent a fourth HSCT. Twenty-one patients
had a bacterial or fungal infection at the time of transplantation. In patients
with multiple HSCTs, each transplantation was analyzed separately.
BSI was deﬁned as isolation of 1 or more recognized bacterial or fungal
pathogens from 1 ormore blood cultures and at least 1 of the following signs
and symptoms within 24 hours of collection of a positive blood culture:
fever (>38C), chills or rigors, or hypotension. We classiﬁed ABO compati-
bility as minor (eg, from an type O donor to a type A, B, or AB recipient),
major (eg, from a type A, AB, or B donor to an type O recipient), and major
and minor (eg, type A donor to type B recipient). We deﬁned an HLA match
donor as a 6/6 HLA-A, -B, and -DR antigen match between recipient and
donor, using low-resolution typing. The median duration of follow-up was
39 months. Data collected as of October 2012 were analyzed.
In univariate analysis, the chi square test and Fisher’s exact test were
used to assess risk factors for BSI. Multivariate stepwise regression was
performed to explore the independent effects of variables that demon-
strated a signiﬁcant inﬂuence in univariate analysis (P< .10). Overall survival
was analyzed using the Kaplan-Meier method, with differences compared
using the log-rank test. Statistical analyses were performed using SPSS 11.0
for Windows release 11.0.1J (SPSS Japan, Tokyo, Japan).Figure 1. Kaplan-Meier estimate of overall survival for patients with BSI
(n ¼ 40; 63.68%  7.87%) and patients without BSI (n ¼ 311; 93.65%  1.41%);
P < .0001.RESULTS
Assessment of BSI in All 351 Patients Who Underwent
HSCT
BSI occurred in 39 of the 351 patients with AA (11.1%).
Onset of BSI occurred at a median of 8 days after trans-
plantation (range, 0 to 92 days). The bacteria that were iso-
lated are summarized in Table 1. Staphylococcus spp were
detected in 11 patients, and Streptococcus spp were detected
in 7 patients. Gram-positive cocci were detected in 20 pa-
tients (51.3%); gram-positive bacilli, in 5 patients (12.8%);
gram-negative bacilli, in 11 patients (28.2%); and Candida
spp, in 3 patients (7.7%). The 5-year overall survival rate was
lower in patients with BSI compared with patients without
BSI (65.32%  7.90% versus 93.35%  1.44%; P < .0001)(Figure 1). The cause of death was directly associated with
BSI in 5 of the 13 patients with BSI who died.
We performed univariate and multivariate analyses to
identify risk factors for BSI in the patients with AA (Table 2).
Variables associated with BSI on univariate analysis included
(1) history of immunosuppressive therapy with ATG, (2)
transplantation from an unrelated donor, (3) frequent blood
transfusions before HSCT, (4) major or major plus minor ABO
mismatch, (5) tacrolimus as acute GVHD prophylaxis with
use of CsA, and (6) extended interval from diagnosis of AA to
HSCT. Infectious complications at the time of HSCT were not
associated with BSI after transplantation. Multivariate anal-
ysis identiﬁed extended interval from diagnosis to HSCT
(>300 days) as the sole statistically signiﬁcant risk factor for
BSI (Table 3).
Assessment of BSI in 158 Patients Who Underwent First
HSCT from a Related Donor
BSI occurred in 11 of 158 patients with AA who under-
went ﬁrst HSCT from a related donor (7.0%). The 5-year
overall survival rate was lower in patients with compli-
cated BSI compared with patients without BSI (81.82% 
Table 2
Clinical Characteristics of 351 Patients Who Underwent HSCT
BSI
(n ¼ 39)
No BSI
(n ¼ 312)
P
Sex, male/female, n 21/18 172/140 1.000
Age, yr, median 11 11 .568
Previous treatment, n (%)
ATG 33 (85) 177 (57) .001
CsA 34 (87) 210 (67) .010
Both ATG and CsA 33 (85) 171 (55) <.001
Bacterial/fungal infection at
HSCT, n (%)
3 (8) 18 (6) .716
First HSCT, n (%) 37 (95) 286 (92) .754
Stem cell source, n (%) .959
BM 35 (90) 280 (90)
PB 1 (3) 11 (4)
BM þ PB 0 (0) 1 (0)
CB 3 (8) 20 (6)
Donor, n (%) .044
Syngeneic 0 (0) 1 (0)
Related 12 (31) 161 (52)
Unrelated 27 (69) 150 (48)
Receipt of 20 transfusions
before HSCT, n (%)
RBCs 20 (51) 84 (27) .003
Platelets 21 (54) 102 (33) .012
ABO type match, n (%) .014
Match 16 (41) 172 (55)
Major mismatch 14 (36) 47 (15)
Minor mismatch 6 (15) 54 (17)
Major plus minor mismatch 3 (8) 39 (13)
HLA compatibility (low-resolution
typing), n (%)
.846
Matched 30 (77) 231 (74)
Mismatched 9 (23) 81 (26)
Conditioning regimen, n (%)
ATG 30 (77) 210 (67) .275
Fludarabine 27 (69) 217 (70) 1.000
Cyclophosphamide 36 (92) 281 (90) 1.000
Irradiation 33 (85) 231 (74) .173
GVHD prophylaxis, n (%)
Steroid 0 (0) 17 (5) .235
CsA 11 (28) 149 (48) .040
Tacrolimus 28 (72) 163 (52) .026
Methotrexate 37 (95) 282 (90) .555
Acute GVHD grade II-IV, n (%) 5 (13) 55 (18) .651
Graft failure, n (%) 5 (13) 16 (5) .070
Time from diagnosis to HSCT, d,
median
447 305.5 .020
Time from diagnosis to
HSCT >300 d, n (%)
30 (77) 157 (50) .002
Severity at diagnosis, n (%) .641
Very severe 7 (18) 77 (25)
Severe 16 (41) 121 (39)
Nonsevere 16 (41) 114 (37)
Severity at HSCT, n (%) .426
Very severe 17 (44) 105 (34)
Severe 15 (38) 151 (48)
Nonsevere 7 (18) 56 (18)
BM indicates bone marrow; PB, peripheral blood; CB, cord blood.
*Irradiation included total body irradiation, thoracoabdominal irradiation,
and total lymphoid irradiation.
Table 3
Multivariate Analysis of 351 Patients with AA
Hazard
Ratio
P 95% Conﬁdence
Interval
Interval from diagnosis to
HSCT >300 d
2.430 .041 1.036-5.702
20 RBC or platelet
transfusions before HSCT
1.843 .109 0.873-3.891
Major or major plus minor
ABO type mismatch
1.595 .199 0.783-3.250
Unrelated donor 1.233 .673 0.466-3.262
Use of tacrolimus 1.167 .755 0.442-3082
Previous treatment with ATG
or CsA
1.115 .839 0.392-3.170
R. Kobayashi et al. / Biol Blood Marrow Transplant 20 (2014) 1145e1149 114711.63% versus 95.84%  1.66%; P ¼ .0379). Univariate analysis
of variables associated with BSI identiﬁed age 14 years at
HSCT as the sole risk factor (Table 4).
Assessment of BSI in 165 Patients Who Underwent First
HSCT from an Unrelated Donor
BSI occurred in 26 of 165 patients with AA who under-
went a ﬁrst HSCT from an unrelated donor (15.8%). The 5-
year overall survival rate was lower in patients with
complicated BSI compared with those without BSI (55.75% 
10.14% versus 90.77%  2.25%; P < .0001). In univariateanalysis, variables associated with BSI included a history
of immunosuppressive therapy with ATG, frequent blood
transfusion before transplantation, graft failure, and major or
major plus minor ABO type mismatch (Table 4).
DISCUSSION
In the literature, the incidence of BSI after the early phase
of HSCT in children has ranged from 25% to 30% [4-8]. In our
previous study, the incidence of BSI after HSCT (including
patients with malignant and nonmalignant diseases) was
8.7% [6]. In the study of Sarashina et al. [6], nonmalignant
disease, especially AA and Wiskott-Aldrich syndrome, were
identiﬁed as risk factors for BSI after HSCT (17.2%).
The present study is the ﬁrst to analyze BSI after HSCT in
pediatric patients with AA. Our data show a lower incidence
of BSI in these patients (11.1%) compared with our previous
study, but a higher incidence than that seen in patients with
other diseases in that study. In our previous study, BSI was
not associated with survival, and the survival rate was nearly
identical in patients with BSI and those without BSI; how-
ever, in the present study, the survival rate was lower in
patients with BSI. Patients with malignant diseases were
included in the previous study, whereas only patients with
AA were analyzed in the present study. In patients with
malignant disease, the relapse rate of the original disease
was lower in patients with BSI; this difference might account
for the discrepant results between the previous and present
studies.
In the present study, univariate analysis identiﬁed a his-
tory of immunosuppressive therapy with ATG, receipt of a
transplant from an unrelated donor, frequent blood trans-
fusions before HSCT, major or major plus minor ABO type
mismatch, GVHD prophylaxis with tacrolimus but without
CsA, and extended interval from diagnosis to HSCT as risk
factors for BSI. Poutsiaka et al. [9] previously reported an
association between BSI after HSCT and acute GVHD; how-
ever, our data do not corroborate this ﬁnding. Interestingly,
the risk factors for BSI identiﬁed in the present study are
associated with one another. Generally, patients without a
related HLA-matched donor are treated with immunosup-
pressive therapy. If this therapy is not effective, then HSCT
with an unrelated donor is performed. These patients often
receive numerous blood transfusions and have a extended
interval between diagnosis and transplantation. Further-
more, tacrolimus (rather than CsA)may be selected for GVHD
prophylaxis. Among these factors, an extended interval be-
tween diagnosis and HSCT was the sole statistically signiﬁ-
cant risk factor for BSI identiﬁed by multivariate analysis.
Regarding numerous blood transfusions before HSCT,
some recent studies have investigated the relationship
Table 4
Clinical characteristics of 158 patients who underwent HSCT from related donor as ﬁrst HSCT and 165 patients who underwent HSCT from unrelated donor as
ﬁrst HSCT
Related Donor (n ¼ 158) Unrelated Donor (n ¼ 165)
BSI
(n ¼ 11)
No BSI
(n ¼ 147)
P BSI
(n ¼ 26)
No BSI
(n ¼ 139)
P
Sex, male/female, n 6/5 84/63 1.000 10/16 77/62 .136
Age, yr, median 15 11 .050 11 11 .675
Age 14 yr, n (%) 8 (73) 45 (31) .007
Previous treatment, n (%)
ATG 5 (45) 49 (33) .512 25 (96) 110 (79) .050
CsA 6 (56) 68 (46) .756 25 (96) 124 (89) .472
Both ATG and CsA 5 (45) 48 (33) .509 25 (96) 107 (77) .030
Bacterial/fungal infection at HSCT, n (%) 2 (18) 10 (7) .198 1 (4) 7 (5) 1.000
Stem cell source, n (%) .863 .734
BM 10 (91) 139 (95) 23 (88) 125 (90)
PB 1 (9) 6 (4) 0 (0) 0 (0)
BM þ PB 0 (0) 1 (1) 0 (0) 0 (0)
CB 0 (0) 1 (1) 3 (12) 14 (10)
Donor, n (%) 1.000
Syngeneic 0 (0) 1 (1) - -
Related 11 (100) 146 (99) - -
Receipt of 20 transfusions before HSCT, n (%)
RBCs 2 (18) 10 (7) .198 17 (65) 57 (41) .031
Platelets 3 (27) 26 (18) .425 17 (65) 58 (42) .032
ABO type match, n (%) .718 .024
Match 7 (64) 97 (66) 8 (31) 62 (45)
Major mismatch 2 (18) 18 (12) 12 (46) 26 (19)
Minor mismatch 2 (18) 20 (14) 3 (12) 29 (21)
Major and minor mismatch 0 (0) 12 (8) 3 (12) 22 (16)
HLA compatibility (low-resolution typing), n (%) 1.000 .248
Matched 9 (82) 122 (83) 21 (78) 95 (68)
Mismatched 2 (18) 25 (17) 5 (22) 44 (32)
Conditioning regimen, n (%)
ATG 7 (64) 91 (62) 1.000 22 (81) 108 (78) .602
Fludarabine 5 (45) 87 (59) .528 20 (77) 109 (78) .333
Cyclosphosphamide 10 (91) 138 (94) .525 24 (92) 130(94) .685
Irradiation 6 (56) 85 (58) 1.000 25 (96) 128 (92) .693
GVHD prophylaxis, n (%)
Steroid 0 (0) 4 (3) 1.000 0 (0) 10 (7) .365
CsA 10 (91) 119 (81) .690 1 (4) 20 (14) .203
Tacrolimus 1 (9) 28 (19) .690 25 (96) 119 (86) .203
Methotrexate 10 (91) 131 (89) 1.000 25 (96) 132 (95) 1.000
Acute GVHD grade II-IV, n (%) 0 (0) 13 (9) .601 5 (19) 37 (27) .624
Graft failure, n (%) 0 (0) 5 (3) 1.000 5 (19) 7 (5) .024
Mean time from diagnosis to HSCT, d 91 80 .426 474.5 455 .183
Severity at diagnosis, n (%) .735 .664
Very severe 2 (18) 41 (28) 5 (19) 35 (25)
Severe 5 (45) 65 (44) 10 (38) 42 (30)
Nonsevere 4 (36) 41 (28) 11 (42) 62 (45)
Severity at HSCT, n (%) .490 .094
Very severe 5 (45) 59 (40) 12 (46) 35 (25)
Severe 3 (27) 64 (44) 10 (38) 75 (54)
Nonsevere 3 (27) 24 (16) 4 (15) 29 (21)
*Irradiation included total body irradiation, thoracoabdominal irradiation, and total lymphoid irradiation.
R. Kobayashi et al. / Biol Blood Marrow Transplant 20 (2014) 1145e11491148between pretransplantation hyperferritinemia and post-
transplantation outcomes [10,11]. In many of these reports,
hyperferritinemia was associated with adverse outcomes
after allogeneic HSCT. Moreover, iron overload is associated
with proliferation of bacteria and fungus [12]. These obser-
vations suggest that iron chelating agents should be
administered before HSCT in patients who have received
frequent blood transfusions.
We analyzed BSI after HSCT in patients undergoing ﬁrst
transplantation from related and unrelated donors to clarify
the risk factors for BSI. In both groups, survival rates were
signiﬁcantly lower in patients with BSI than in those without
BSI. Surprisingly, the survival rate of patients undergoing
HSCT from an unrelated donor without BSI exceeded 90%,
not signiﬁcantly different from that seen in patients under-
going HSCT from a related donor. This ﬁnding suggests thatprevention of BSI is important to improving outcomes after
HSCT. In patients who underwent HSCT from a related donor,
age 14 years at transplantation was identiﬁed as a risk
factor for BSI, although the incidence of BSI was evidently
lower than that in patients undergoing HSCT from an unre-
lated donor. Older patients tend to have more severe oral
mucositis. Furthermore, we previously identiﬁed age >10
years as a risk factor for fungal infection in patients with
hematologic malignancies [13]. In contrast, in patients who
underwent HSCT from an unrelated donor, variables associ-
ated with BSI included a history of immunosuppressive
therapy with ATG, frequent transfusions before trans-
plantation, graft failure, and major or major plus minor ABO
type mismatch.
The impact of ABO incompatibility on clinical outcomes
remains controversial [14,15]. ABO incompatibility in
R. Kobayashi et al. / Biol Blood Marrow Transplant 20 (2014) 1145e1149 1149allogeneic HSCT is associated with an increased risk of
delayed erythroid reconstitution, pure RBC aplasia, and acute
and delayed hemolysis; however, ABO incompatibility has
not been identiﬁed as a risk factor for BSI. The ABO blood
group antigens consist of oligosaccharide glycoproteins and
are expressed in erythrocytes as well as in neutrophils,
platelets, and vascular endothelial and epithelial cells. The
ABO antigens could be immunologic targets for ABO-
incompatible donor or recipient lymphocytes, thereby
affecting GVHD and engraftment [16]. These phenomena
may contribute to the development of BSI.
In conclusion, because the 5-year overall survival rate
without BSI exceeded 90%, even in patients who underwent
HSCT from an unrelated donor, controlling BSI is very
important for a successful outcome of HSCT in patients with
pediatric AA.
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